Benary G, Kilgenstein F, Koller S, Scherkenbeck J
RSC Adv. 2025; 15(2):883-895.
PMID: 39802464
PMC: 11719397.
DOI: 10.1039/d4ra08503e.
Shi Y, Zheng H, Wang T, Zhou S, Zhao S, Li M
Mol Cancer. 2025; 24(1):9.
PMID: 39799325
PMC: 11724471.
DOI: 10.1186/s12943-024-02216-3.
Iwamoto K, Matsuoka S, Ueda M
Nat Commun. 2025; 16(1):117.
PMID: 39746985
PMC: 11696275.
DOI: 10.1038/s41467-024-55389-2.
Bhinderwala F, Gronenborn A
J Am Chem Soc. 2024; 147(1):1028-1033.
PMID: 39693054
PMC: 11719398.
DOI: 10.1021/jacs.4c14294.
Wang B, Yang R, Wan C, Tian Y, Wu J, Roy S
bioRxiv. 2024; .
PMID: 39554064
PMC: 11565788.
DOI: 10.1101/2024.10.30.620932.
Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?.
Healy F, Turner A, Marensi V, MacEwan D
Front Pharmacol. 2024; 15:1441938.
PMID: 39372214
PMC: 11450236.
DOI: 10.3389/fphar.2024.1441938.
Surface-mutagenesis strategies to enable structural biology crystallization platforms.
Schaefer M, Putter V, Hilpmann A, Egner U, Holton S, Hillig R
Acta Crystallogr D Struct Biol. 2024; 80(Pt 9):661-674.
PMID: 39207897
PMC: 11394123.
DOI: 10.1107/S2059798324007939.
Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody.
Jungholm O, Trkulja C, Moche M, Srinivasa S, Christakopoulou M, Davidson M
Sci Rep. 2024; 14(1):19656.
PMID: 39179604
PMC: 11344056.
DOI: 10.1038/s41598-024-70217-9.
Development and tissue specific expression of RAPGEF1 (C3G) transcripts having exons encoding disordered segments with predicted regulatory function.
Verma A, Goel A, Koner N, Gunasekaran G, Radha V
Mol Biol Rep. 2024; 51(1):907.
PMID: 39141165
DOI: 10.1007/s11033-024-09845-3.
Allosteric nanobodies to study the interactions between SOS1 and RAS.
Fischer B, Uchanski T, Sheryazdanova A, Gonzalez S, Volkov A, Brosens E
Nat Commun. 2024; 15(1):6214.
PMID: 39043660
PMC: 11266648.
DOI: 10.1038/s41467-024-50349-2.
Bimodality in Ras signaling originates from processivity of the Ras activator SOS without deterministic bistability.
Lee A, Kim N, Alvarez S, Ren H, DeGrandchamp J, Lew L
Sci Adv. 2024; 10(25):eadi0707.
PMID: 38905351
PMC: 11192083.
DOI: 10.1126/sciadv.adi0707.
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Sudhakar N, Yan L, Qiryaqos F, Engstrom L, Laguer J, Calinisan A
Mol Cancer Ther. 2024; 23(10):1418-1430.
PMID: 38904222
PMC: 11443210.
DOI: 10.1158/1535-7163.MCT-23-0870.
Targeting guanine nucleotide exchange factors for novel cancer drug discovery.
Bannoura S, Khan H, Uddin M, Mohammad R, Pasche B, Azmi A
Expert Opin Drug Discov. 2024; 19(8):949-959.
PMID: 38884380
PMC: 11380440.
DOI: 10.1080/17460441.2024.2368242.
Molecular Mechanism of Phosphorylation-Mediated Impacts on the Conformation Dynamics of GTP-Bound KRAS Probed by GaMD Trajectory-Based Deep Learning.
Chen J, Wang J, Yang W, Zhao L, Zhao J, Hu G
Molecules. 2024; 29(10).
PMID: 38792177
PMC: 11123822.
DOI: 10.3390/molecules29102317.
Combinatorially restricted computational design of protein-protein interfaces to produce IgG heterodimers.
Azzam T, Du J, Flowers M, Ali A, Hunn J, Vijayvargiya N
Sci Adv. 2024; 10(15):eadk8157.
PMID: 38598628
PMC: 11006224.
DOI: 10.1126/sciadv.adk8157.
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies.
Linehan A, OReilly M, McDermott R, OKane G
Front Med (Lausanne). 2024; 11:1369136.
PMID: 38576709
PMC: 10991798.
DOI: 10.3389/fmed.2024.1369136.
Progress in Targeting KRAS Directly.
Nissley D, Stephen A, Yi M, McCormick F
Methods Mol Biol. 2024; 2797:1-12.
PMID: 38570448
DOI: 10.1007/978-1-0716-3822-4_1.
Stereoselective Amine Synthesis Mediated by a Zirconocene Hydride to Accelerate a Drug Discovery Program.
Aloiau A, Bobek B, Caddell Haatveit K, Pearson K, Watkins A, Jones B
J Org Chem. 2024; 89(6):3875-3882.
PMID: 38422508
PMC: 10949245.
DOI: 10.1021/acs.joc.3c02723.
Adapting recombinant bacterial alkaline phosphatase for nucleotide exchange of small GTPases.
Frank P, Hong M, Higgins B, Perkins S, Taylor T, Wall V
Protein Expr Purif. 2024; 218:106446.
PMID: 38395209
PMC: 11000209.
DOI: 10.1016/j.pep.2024.106446.
Role of c-Src in Carcinogenesis and Drug Resistance.
Raji L, Tetteh A, Amin A
Cancers (Basel). 2024; 16(1).
PMID: 38201459
PMC: 10778207.
DOI: 10.3390/cancers16010032.